Use of economic evaluations varies by drug & place

• More likely to be used if drug has:

  • high budget impact
  • marginal benefit but at high cost
  • innovative

• Less likely to be used if drug has:

  • weak clinical evidence
  • penetrated market
  • Or where other decision criteria are key (ethics, politics)

Previous slide

Next slide

Back to first slide

View graphic version